Asset profile
Descartes-08
Cell therapy
Evidence outlook · program status
Discontinued (2026-04-30), as a strategic decision by the sponsor
Cartesian Therapeutics (RNAC), Q1 2026 results 8-K exhibit 99.1 dated 2026-04-30, fetched 2026-09-02: the company decided to stop developing Descartes-08 in systemic lupus erythematosus (sic 'systematic' in the source). The registry record NCT06038474 (Phase 2 SLE, primary completion 2026-12-01) still reads ACTIVE_NOT_RECRUITING, last updated 2026-03-27, before the decision; the catalyst screen surfaced it in analyst digest 2 as a live readout. The company's active Descartes-08 programs are outside this site's built markets: Phase 3 AURORA in myasthenia gravis (NCT06799247, n=128, data expected 1Q27, BLA mid-2027 per the 2026-08-06 Q2 release), Phase 2 TRITON in myositis, Phase 1/2 HELIOS pediatric. Market-scoped row only: the whole program is active. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
Also in development:Systemic Lupus Erythematosus · Phase 2Dermatomyositis · Phase 1/2
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
59 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 59 same-indication; 8 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Descartes-08: this drug | Phase 3 | Cell therapy | — | ||
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Belimumab (GSK1550188) | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) | ||
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | ||
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | ||
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | ||
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | ||
| Voclosporin (Lupkynis) | Approved | Small molecule | Calcineurin, Cyclophilin A (leading to calcineurin inhibition) | ||
| APG-2575(Lisaftoclax ) | Phase 3 | Small molecule | BCL-2 | ||
| AZD0120 | Phase 3 | Cell therapy | BCMA / CD19 | ||
| Blinatumomab | Phase 3 | Multispecific antibody | CD19 x CD3 | ||
| Cemdisiran | Phase 3 | RNA / oligonucleotide | Complement C5 | ||
| Divozilimab | Phase 3 | Monoclonal antibody | CD20 | ||
| Envudeucitinib | Phase 3 | Small molecule | TYK2 | ||
| Frexalimab | Phase 3 | Monoclonal antibody | CD40 ligand (CD40L / CD154) |
…and 44 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.